These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 25417601)

  • 41. Metformin and the mTOR inhibitor everolimus (RAD001) sensitize breast cancer cells to the cytotoxic effect of chemotherapeutic drugs in vitro.
    Liu H; Scholz C; Zang C; Schefe JH; Habbel P; Regierer AC; Schulz CO; Possinger K; Eucker J
    Anticancer Res; 2012 May; 32(5):1627-37. PubMed ID: 22593441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
    Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
    Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolic switching in the hypoglycemic and antitumor effects of metformin on high glucose induced HepG2 cells.
    Lv Y; Tian N; Wang J; Yang M; Kong L
    J Pharm Biomed Anal; 2018 Jul; 156():153-162. PubMed ID: 29705631
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Molecular action of insulin-sensitizing agents].
    Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
    Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
    Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
    Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effects of metformin on the estrogen-induced proliferation and the expression of ER in human endometrial cancer cells].
    Zhang J; Zhang B; Yin Z; Chen F; Liu T; Xu H; Liu Y; Zhou X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):932-7. PubMed ID: 25608995
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
    Mackay HJ; Eisenhauer EA; Kamel-Reid S; Tsao M; Clarke B; Karakasis K; Werner HM; Trovik J; Akslen LA; Salvesen HB; Tu D; Oza AM
    Cancer; 2014 Feb; 120(4):603-10. PubMed ID: 24166148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.
    Rocha GZ; Dias MM; Ropelle ER; Osório-Costa F; Rossato FA; Vercesi AE; Saad MJ; Carvalheira JB
    Clin Cancer Res; 2011 Jun; 17(12):3993-4005. PubMed ID: 21543517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
    Kalinsky K; Crew KD; Refice S; Xiao T; Wang A; Feldman SM; Taback B; Ahmad A; Cremers S; Hibshoosh H; Maurer M; Hershman DL
    Cancer Invest; 2014 May; 32(4):150-7. PubMed ID: 24605899
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metformin use and gynecological cancers: A novel treatment option emerging from drug repositioning.
    Gadducci A; Biglia N; Tana R; Cosio S; Gallo M
    Crit Rev Oncol Hematol; 2016 Sep; 105():73-83. PubMed ID: 27378194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metformin - its potential anti-cancer and anti-aging effects.
    Podhorecka M; Ibanez B; Dmoszyńska A
    Postepy Hig Med Dosw (Online); 2017 Mar; 71(0):170-175. PubMed ID: 28258677
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer.
    Yates MS; Coletta AM; Zhang Q; Schmandt RE; Medepalli M; Nebgen D; Soletsky B; Milbourne A; Levy E; Fellman B; Urbauer D; Yuan Y; Broaddus RR; Basen-Engquist K; Lu K
    Cancer Prev Res (Phila); 2018 Aug; 11(8):477-490. PubMed ID: 29716897
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma.
    Slomovitz BM; Jiang Y; Yates MS; Soliman PT; Johnston T; Nowakowski M; Levenback C; Zhang Q; Ring K; Munsell MF; Gershenson DM; Lu KH; Coleman RL
    J Clin Oncol; 2015 Mar; 33(8):930-6. PubMed ID: 25624430
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis.
    Xue J; Zhang H; Liu W; Liu M; Shi M; Wen Z; Li C
    Reproduction; 2013 Oct; 146(4):397-406. PubMed ID: 23904524
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.
    Dong L; Zhou Q; Zhang Z; Zhu Y; Duan T; Feng Y
    J Obstet Gynaecol Res; 2012 Aug; 38(8):1077-85. PubMed ID: 22540333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R.
    Zhang Y; Li MX; Wang H; Zeng Z; Li XM
    Asian Pac J Cancer Prev; 2015; 16(1):221-5. PubMed ID: 25640355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison between the effects of metformin and megestrol on simple endometrial hyperplasia.
    Sharifzadeh F; Aminimoghaddam S; Kashanian M; Fazaeli M; Sheikhansari N
    Gynecol Endocrinol; 2017 Feb; 33(2):152-155. PubMed ID: 27690687
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKα.
    Yan M; Qi H; Xia T; Zhao X; Wang W; Wang Z; Lu C; Ning Z; Chen H; Li T; Tekcham DS; Liu X; Liu J; Chen D; Liu X; Xu G; Piao HL
    Metabolism; 2019 Feb; 91():18-29. PubMed ID: 30468782
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antihyperglycemic mechanism of metformin occurs via the AMPK/LXRα/POMC pathway.
    Cho K; Chung JY; Cho SK; Shin HW; Jang IJ; Park JW; Yu KS; Cho JY
    Sci Rep; 2015 Jan; 5():8145. PubMed ID: 25634597
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study.
    Niraula S; Dowling RJ; Ennis M; Chang MC; Done SJ; Hood N; Escallon J; Leong WL; McCready DR; Reedijk M; Stambolic V; Goodwin PJ
    Breast Cancer Res Treat; 2012 Oct; 135(3):821-30. PubMed ID: 22933030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.